Freestone Capital Holdings’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-3,076
Closed -$230K 510
2021
Q3
$230K Sell
3,076
-50
-2% -$4.2K 0.01% 385
2021
Q2
$289K Hold
3,126
0.01% 351
2021
Q1
$277K Buy
3,126
+2,826
+942% +$280K 0.02% 340
2020
Q4
$28K Buy
+300
New +$23.9K ﹤0.01% 680

Other funds holding ARKG

Freestone Capital Holdings's ARKG Position: Q4 2021 in Review

Freestone Capital Holdings sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2021, closing a stake of 3,076 shares — an estimated $230K sold.

Freestone Capital Holdings first reported a position in ARKG in Q4 2020 and held it in 4 quarters. The position peaked at $289K in Q2 2021. 460 funds tracked by Wall St. Rank hold ARKG as of Q4 2021.

  • Freestone Capital Holdings reported no remaining ARK Genomic Revolution ETF position as of Q4 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 3,076 ARK Genomic Revolution ETF shares in Q4 2021, an estimated $230K.
  • Freestone Capital Holdings first reported a position in ARK Genomic Revolution ETF in Q4 2020 and held it in 4 quarters.
  • Freestone Capital Holdings's ARK Genomic Revolution ETF position peaked at $289K in Q2 2021.
  • 460 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2021.

Based on Freestone Capital Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.